Braveheart Bio, Inc.
BRVE Nasdaq
SEC CIK 2131524
Follow Braveheart Bio
Weekly email: filings, results
Net income
−$26.5M
+55.2% vs same quarter last year
EPS, diluted
−$0.51
+94.9% vs same quarter last year
Operating cash flow
−$24.4M
−3193.6% vs same quarter last year
Operating income
−$30.1M
+49.1% vs same quarter last year
Source: SEC XBRL filings · latest filing